Phaseline

Companies › Opna Bio

Opna Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OPN-6602
EP300 and CBP bromodomain inhibitor
EP300, CBPPhase 1Relapsed Multiple MyelomaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06433947OPN-6602Phase 1Relapsed Multiple MyelomaOncologyDec 2027

Targets

EP300 (1) CBP (1)

Companies with the same targets

Pathos AI

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.